AP1754A - Pharmaceutical compositions based on azetidine derivatives. - Google Patents
Pharmaceutical compositions based on azetidine derivatives.Info
- Publication number
- AP1754A AP1754A APAP/P/2004/003066A AP2004003066A AP1754A AP 1754 A AP1754 A AP 1754A AP 2004003066 A AP2004003066 A AP 2004003066A AP 1754 A AP1754 A AP 1754A
- Authority
- AP
- ARIPO
- Prior art keywords
- azetidine
- general formula
- optionally
- pharmaceutical compositions
- derivatives
- Prior art date
Links
- 150000001539 azetidines Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108050007331 Cannabinoid receptor Proteins 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000084 colloidal system Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 230000003381 solubilizing effect Effects 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention concerns a stable pharmaceutical composition comprising at least an azetidine derivative of general formula (la) or (Ib), wherein: Ar is aromatic or heteroaromatic group optionally substituted by one or several C1-C4, alkyl, halogen, NO2, CN C1-C4 alkoxy or OH, optionally combined with another active principle capable of potentiating the effects of the azetidine derivative of general formula (la) or (Ib), in a system comprising not more than two main excipients selected among a non-ionic surfactant with hydrophilic character capable of solubilizing the azetidine derivatrve of general formula (la) or (Ib) and optionally the active principle potentiating the effects of the azetidine derivative, and capable of causing the formation of a colloidal system, optionally with addition of a second lipophilic excipient, stabilizing the formulation. The pharmaceutical compositions comprising azetidine derivatives of formulae (la) or (Ib) are particularly useful because of the high affinity of said derivatives for cannabinoid receptors.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0116638A FR2833842B1 (en) | 2001-12-21 | 2001-12-21 | PHARMACEUTICAL COMPOSITIONS BASED ON AZETIDINE DERIVATIVES |
| PCT/FR2002/004514 WO2003053431A2 (en) | 2001-12-21 | 2002-12-20 | Pharmaceutical compositions based on azetidine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP2004003066A0 AP2004003066A0 (en) | 2004-06-30 |
| AP1754A true AP1754A (en) | 2007-07-18 |
Family
ID=8870824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/2004/003066A AP1754A (en) | 2001-12-21 | 2002-12-20 | Pharmaceutical compositions based on azetidine derivatives. |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP1458413B1 (en) |
| JP (1) | JP5021887B2 (en) |
| KR (1) | KR20040068308A (en) |
| CN (1) | CN100388918C (en) |
| AP (1) | AP1754A (en) |
| AR (1) | AR037687A1 (en) |
| AU (1) | AU2002364866B2 (en) |
| BR (1) | BR0215048A (en) |
| CA (1) | CA2470443A1 (en) |
| CO (1) | CO5590911A2 (en) |
| DE (1) | DE60233071D1 (en) |
| DK (1) | DK1458413T3 (en) |
| EA (1) | EA006510B1 (en) |
| EC (1) | ECSP045162A (en) |
| FR (1) | FR2833842B1 (en) |
| HR (1) | HRP20040575A2 (en) |
| HU (1) | HUP0402586A3 (en) |
| IL (1) | IL162563A0 (en) |
| MA (1) | MA27086A1 (en) |
| ME (1) | MEP16608A (en) |
| MX (1) | MXPA04005558A (en) |
| MY (1) | MY138172A (en) |
| NO (1) | NO20042781L (en) |
| NZ (1) | NZ533225A (en) |
| OA (1) | OA12750A (en) |
| PL (1) | PL203248B1 (en) |
| RS (1) | RS55504A (en) |
| TW (1) | TWI256304B (en) |
| UA (1) | UA77736C2 (en) |
| WO (1) | WO2003053431A2 (en) |
| ZA (1) | ZA200404338B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1498122A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Semi-solid systems containing azetidine derivatives |
| EP1498123A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Emulsifying systems containing azetidine derivatives |
| BRPI0507801A (en) | 2004-02-17 | 2007-07-10 | Esteve Labor Dr | substituted azetidine compounds, process for preparing substituted azetidine compounds, medicament and use of at least one substituted azetidine compound |
| FR2879932B1 (en) * | 2004-12-27 | 2007-03-23 | Aventis Pharma Sa | FORMULATIONS INJECTABLE OR ORALLY ADMINISTRATIVE OF AZETIDINE DERIVATIVES |
| NZ564759A (en) | 2005-06-30 | 2011-08-26 | Prosidion Ltd | GPCR agonists |
| AR064736A1 (en) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | GPCR AGONISTS |
| BRPI0806498A2 (en) | 2007-01-04 | 2014-04-22 | Prosidion Ltd | GPCR PIPERIDINE AGONISTS |
| WO2008081208A1 (en) | 2007-01-04 | 2008-07-10 | Prosidion Limited | Piperidine gpcr agonists |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| CL2008000018A1 (en) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | COMPOUNDS DERIVED FROM NITROGEN AND OXYGEN HETEROCICLES, GPCR AGONISTS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF OBESITY, DIABETES, METABOLIC SYNDROME, HYPERLIPIDEMIA, TOLERANCE |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| FR2923719B1 (en) * | 2007-11-15 | 2009-11-20 | Sanofi Aventis | PHARMACEUTICAL COMPOSITIONS BASED ON AZETIDINE DERIVATIVES |
| FR2928149B1 (en) | 2008-02-29 | 2011-01-14 | Sanofi Aventis | AZETIDINE-DERIVED COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| FR2946650B1 (en) * | 2009-06-16 | 2011-08-19 | Sanofi Aventis | ESTERS DERIVED FROM AZETIDINES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS. |
| UA153183U (en) | 2022-10-27 | 2023-05-31 | Андрій Валерійович Максимов | GLASS FOR DRINK PREPARATION |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000015609A1 (en) * | 1998-09-11 | 2000-03-23 | Aventis Pharma S.A. | Azetidine derivatives, preparation and medicines containing them |
| WO2001064633A1 (en) * | 2000-03-03 | 2001-09-07 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof |
| WO2001064634A1 (en) * | 2000-03-03 | 2001-09-07 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR73668B (en) * | 1978-11-21 | 1984-03-28 | Hoffmann La Roche | |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| HRP980026A2 (en) * | 1998-01-20 | 1999-10-31 | Pliva Pharm & Chem Works | 1-izothiazolydinone derivatives of azetidine-2-ones, processes for the preparation and use thereof |
| WO2000003753A2 (en) * | 1998-07-14 | 2000-01-27 | Em Industries, Inc. | Microdisperse drug delivery systems |
| FR2805818B1 (en) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| FR2814678B1 (en) * | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | COMBINATION OF AN ANTAGONIST OF THE CB1 RECEPTOR AND SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE FOR THE TREATMENT OF OBESITY |
-
2001
- 2001-12-21 FR FR0116638A patent/FR2833842B1/en not_active Expired - Fee Related
-
2002
- 2002-12-02 AR ARP020104646A patent/AR037687A1/en unknown
- 2002-12-03 TW TW091135077A patent/TWI256304B/en active
- 2002-12-20 MX MXPA04005558A patent/MXPA04005558A/en active IP Right Grant
- 2002-12-20 EP EP02801165A patent/EP1458413B1/en not_active Expired - Lifetime
- 2002-12-20 AP APAP/P/2004/003066A patent/AP1754A/en active
- 2002-12-20 JP JP2003554188A patent/JP5021887B2/en not_active Expired - Fee Related
- 2002-12-20 IL IL16256302A patent/IL162563A0/en unknown
- 2002-12-20 HU HU0402586A patent/HUP0402586A3/en unknown
- 2002-12-20 BR BR0215048-4A patent/BR0215048A/en not_active IP Right Cessation
- 2002-12-20 WO PCT/FR2002/004514 patent/WO2003053431A2/en not_active Ceased
- 2002-12-20 HR HR20040575A patent/HRP20040575A2/en not_active Application Discontinuation
- 2002-12-20 NZ NZ533225A patent/NZ533225A/en not_active IP Right Cessation
- 2002-12-20 MY MYPI20024828A patent/MY138172A/en unknown
- 2002-12-20 ME MEP-166/08A patent/MEP16608A/en unknown
- 2002-12-20 DE DE60233071T patent/DE60233071D1/en not_active Expired - Lifetime
- 2002-12-20 OA OA1200400178A patent/OA12750A/en unknown
- 2002-12-20 UA UA20040706001A patent/UA77736C2/en unknown
- 2002-12-20 CA CA002470443A patent/CA2470443A1/en not_active Abandoned
- 2002-12-20 PL PL372708A patent/PL203248B1/en not_active IP Right Cessation
- 2002-12-20 RS YUP-555/04A patent/RS55504A/en unknown
- 2002-12-20 DK DK02801165T patent/DK1458413T3/en active
- 2002-12-20 CN CNB028248406A patent/CN100388918C/en not_active Expired - Fee Related
- 2002-12-20 KR KR10-2004-7009708A patent/KR20040068308A/en not_active Ceased
- 2002-12-20 AU AU2002364866A patent/AU2002364866B2/en not_active Ceased
- 2002-12-20 EA EA200400843A patent/EA006510B1/en not_active IP Right Cessation
-
2004
- 2004-05-21 MA MA27694A patent/MA27086A1/en unknown
- 2004-06-02 ZA ZA200404338A patent/ZA200404338B/en unknown
- 2004-06-17 CO CO04056913A patent/CO5590911A2/en not_active Application Discontinuation
- 2004-06-18 EC EC2004005162A patent/ECSP045162A/en unknown
- 2004-07-01 NO NO20042781A patent/NO20042781L/en not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000015609A1 (en) * | 1998-09-11 | 2000-03-23 | Aventis Pharma S.A. | Azetidine derivatives, preparation and medicines containing them |
| WO2001064633A1 (en) * | 2000-03-03 | 2001-09-07 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof |
| WO2001064634A1 (en) * | 2000-03-03 | 2001-09-07 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003053431A3 (en) | Pharmaceutical compositions based on azetidine derivatives | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| MY136855A (en) | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | |
| CY1108532T1 (en) | UNIONS AND COMPOSITIONS FOR PROVIDING ACTIVE AGENTS | |
| BRPI0416752B8 (en) | pharmaceutical composition, use of one or more compounds, and compounds | |
| PL367618A1 (en) | 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht 7 serotonin receptors | |
| MXPA03007857A (en) | Compounds and compositions for delivering active agents. | |
| DK0991407T4 (en) | Stabilization of acid-sensitive benzimidazoles by amino / cyclodextrin combinations | |
| PT1073470E (en) | Pharmaceutical compositions containing active compounds capable of improving the absorption of active ingredients | |
| NO20000466L (en) | Pharmaceutical preparation for acidic, lipophilic compounds in the form of a self-regulating formulation | |
| CO5560559A2 (en) | FORMULATION OF STABILIZED ORAL SUSPENSION | |
| WO2003045306A3 (en) | Phenoxy amine compounds and compositions for delivering active agents | |
| AU2001296865A1 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
| NO976125D0 (en) | Pharmaceutical amiodarone mixture for parenteral delivery | |
| HRP20020205B1 (en) | DISPERSION FORMULATIONS CONTAINING LIPase INHIBITORS | |
| EP1349545A4 (en) | FENRETINIDE PHARMACEUTICAL COMPOSITIONS HAVING INCREASED BIOAVAILABILITY AND METHODS OF USE | |
| WO2002015959A3 (en) | Compounds and compositions for delivering active agents | |
| MXPA03010054A (en) | Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents. | |
| NO20040589L (en) | Arylsulfonyl derivatives with 5-HT6 receptor affinity. | |
| EP1568382A4 (en) | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND beta-BLOCKER | |
| ATE516016T1 (en) | SELF-EMULSIFYING FORMULATIONS OF CETP INHIBITORS | |
| YU46503A (en) | Pharmaceutical dronedarone composition for parenteral administration | |
| DE60232271D1 (en) | AQUEOUS PHARMACEUTICAL FORMULATIONS OF WATER-SOLUBLE PRODRUGS OF PROPOFOL COMPOUNDS | |
| AR046226A1 (en) | PHARMACEUTICAL FORMULATIONS CONTAINING FLAVOR WITH IMPROVED PHARMACEUTICAL CHARACTERISTICS | |
| EP2319493A3 (en) | Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent |